Literature DB >> 12551804

Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales.

David Cella1, David T Eton, Jin-Shei Lai, Amy H Peterman, Douglas E Merkel.   

Abstract

Magnitude differences in scores on a measure of quality of life that correspond to differences in function or clinical course are called clinically important differences (CIDs). Anchor-based and distribution-based methods were used to provide ranges of CIDs for five targeted scale scores of the Functional Assessment of Cancer Therapy-Anemia (FACT-An) questionnaire. Three samples of cancer patients were used: Sample 1 included 50 patients participating in a validation study of the FACT-An; Sample 2 included 131 patients participating in a longitudinal study of chemotherapy-induced fatigue; sample 3 included 2,402 patients enrolled in a community-based clinical trial evaluating the effectiveness and safety of a treatment for anemia. Three clinical indicators (hemoglobin level; performance status; response to treatment) were used to determine anchor-based differences. One-half of the standard deviation and 1 standard error of measurement were used as distribution-based criteria. Analyses supported the following whole number estimates of a minimal CID for these five targeted scores: Fatigue Scale = 3.0; FACT-G total score = 4.0; FACT-An total score = 7.0; Trial Outcome Index-Fatigue = 5.0; and Trial Outcome Index-Anemia = 6.0. These estimates provide a basis for sample size estimation when planning for a clinical trial or other longitudinal study, when the purpose is to ensure detection of meaningful change over time. They can also be used in conjunction with more traditional clinical markers to assist investigators in determining treatment efficacy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12551804     DOI: 10.1016/s0885-3924(02)00529-8

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  235 in total

1.  Determining clinically important differences in health-related quality of life in older patients with cancer undergoing chemotherapy or surgery.

Authors:  C Quinten; C Kenis; L Decoster; P R Debruyne; I De Groof; C Focan; F Cornelis; V Verschaeve; C Bachmann; D Bron; S Luce; G Debugne; H Van den Bulck; J C Goeminne; A Baitar; K Geboers; B Petit; C Langenaeken; R Van Rijswijk; P Specenier; G Jerusalem; J P Praet; K Vandenborre; M Lycke; J Flamaing; K Milisen; J P Lobelle; H Wildiers
Journal:  Qual Life Res       Date:  2018-12-03       Impact factor: 4.147

Review 2.  ASCPRO recommendations for the assessment of fatigue as an outcome in clinical trials.

Authors:  Andrea M Barsevick; Charles S Cleeland; Donald C Manning; Ann M O'Mara; Bryce B Reeve; Jane A Scott; Jeff A Sloan
Journal:  J Pain Symptom Manage       Date:  2010-06       Impact factor: 3.612

3.  A novel approach to estimate the minimally important difference for the Fatigue Impact Scale in multiple sclerosis patients.

Authors:  Regina Rendas-Baum; Min Yang; Francoise Cattelin; Gene V Wallenstein; John D Fisk
Journal:  Qual Life Res       Date:  2010-07-10       Impact factor: 4.147

4.  Psychological and immunological characteristics of fatigued women undergoing radiotherapy for early-stage breast cancer.

Authors:  Nicholas Courtier; Tina Gambling; Stephanie Enright; Peter Barrett-Lee; Jacinta Abraham; Malcolm D Mason
Journal:  Support Care Cancer       Date:  2012-05-28       Impact factor: 3.603

Review 5.  Quality of life: A critical outcome for all surgical treatments of gastric cancer.

Authors:  Michael D McCall; Peter J Graham; Oliver F Bathe
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

6.  The Testosterone Trials: Seven coordinated trials of testosterone treatment in elderly men.

Authors:  Peter J Snyder; Susan S Ellenberg; Glenn R Cunningham; Alvin M Matsumoto; Shalender Bhasin; Elizabeth Barrett-Connor; Thomas M Gill; John T Farrar; David Cella; Raymond C Rosen; Susan M Resnick; Ronald S Swerdloff; Jane A Cauley; Denise Cifelli; Laura Fluharty; Marco Pahor; Kristine E Ensrud; Cora E Lewis; Mark E Molitch; Jill P Crandall; Christina Wang; Matthew J Budoff; Nanette K Wenger; Emile R Mohler; Diane E Bild; Nakela L Cook; Tony M Keaveny; David L Kopperdahl; David Lee; Ann V Schwartz; Thomas W Storer; William B Ershler; Cindy N Roy; Leslie J Raffel; Sergei Romashkan; Evan Hadley
Journal:  Clin Trials       Date:  2014-06       Impact factor: 2.486

Review 7.  Paroxysmal nocturnal haemoglobinuria.

Authors:  Anita Hill; Amy E DeZern; Taroh Kinoshita; Robert A Brodsky
Journal:  Nat Rev Dis Primers       Date:  2017-05-18       Impact factor: 52.329

8.  A randomized trial of weekly symptom telemonitoring in advanced lung cancer.

Authors:  Susan E Yount; Nan Rothrock; Michael Bass; Jennifer L Beaumont; Deborah Pach; Thomas Lad; Jyoti Patel; Maria Corona; Rebecca Weiland; Katherine Del Ciello; David Cella
Journal:  J Pain Symptom Manage       Date:  2013-11-07       Impact factor: 3.612

9.  A randomised controlled trial to evaluate the efficacy of a 6-month dietary and physical activity intervention for patients receiving androgen deprivation therapy for prostate cancer.

Authors:  Roisin F O'Neill; Farhana Haseen; Liam J Murray; Joe M O'Sullivan; Marie M Cantwell
Journal:  J Cancer Surviv       Date:  2015-04-28       Impact factor: 4.442

10.  Different Phenotyping Approaches Lead to Dissimilar Biologic Profiles in Men With Chronic Fatigue After Radiation Therapy.

Authors:  Li Rebekah Feng; Kristin Dickinson; Neila Kline; Leorey N Saligan
Journal:  J Pain Symptom Manage       Date:  2016-08-09       Impact factor: 3.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.